The middle meningial artery during a migraine attack: 3T magnetic resonance angiography study

Internal Medicine

Volumn 48, Issue 24, 2009, Pages 2133-2135

  Nagata, Eiichiro ^a   Moriguchi, Hisamoto ^a   Takizawa, Shunya ^a   Horie, Tomohiko ^a   Yanagimachi, Noriharu ^a   Takagi, Shigeharu ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

3T magnetic resonance angiography; Middle meningial artery; Migraine

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

ADULT; ARTERY DIAMETER; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN ARTERY; BRAIN BLOOD FLOW; CASE REPORT; DISEASE COURSE; FEMALE; HUMAN; IMAGING SYSTEM; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE MENINGEAL ARTERY; MIGRAINE; MIGRAINE WITHOUT AURA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VASOCONSTRICTION; VASODILATATION;

ADULT; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MAGNETIC RESONANCE ANGIOGRAPHY; MENINGEAL ARTERIES; MIGRAINE WITHOUT AURA; SUMATRIPTAN; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 74549162928     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2565     Document Type: Article

References (13)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med 346: 257-270, 2002.
2. Cumberbatch MJ, Williamson DJ, Mason GS, Hill RG, Hargreaves RJ. Dural vasodilation causes a sensitization of rat caudal trigeminal neurons in vivo that is blocked by a 5-HT1B/1D agonist. Br J Pharmacol 126: 1478-1486, 1999.
3. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 24: 1-160, 2004.
4. Rolan P. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia 17 (Suppl 18): 21-27, 1997.
5. Gupta S, Mehrotra S, Avezaat CJJ, Villalon CM, Saxena PR, Van-DenBrink AM. Characterization of CGRP receptors in the human isolated middle meningeal artery. Life Sci 79: 265-271, 2006.
6. Schoonman GG, van der Grond J, Kortmann C, van der Geest RJ, Terwindt GM, Ferrari MD. Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3T magnetic resonance angiography study. Brain 131: 2192-2200, 2008.
7. Schoonman GG, Bakker D, Schmitz N, et al. Magnetic resonance angiography of the human middle meningeal artery: implications for migraine. J Magn Reson Imaging 24: 918-921, 2006.
8. Leao AAP. Spreading depression of activity in cerebral cortex. J Neurophysiol 7: 359-390, 1944.
9. Cao Y, Welch KMA, Aurora S, Vikingstad EM. Functional MRIBOLD of visually triggered headache in patients with migraine. Arch Neurol 56: 548-554, 1999.
10. Friberg L, Olsen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet 338: 13-17, 1991.
11. Limmroth V, May A, Auerbach P, Wosnitza G, Eppe T, Diener HC. Changes in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine. J Neurol Sci 138: 60-65, 1996.
12. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 19: 115-127, 1999.
13. Cohen AS, Goadsby PJ. Functional neuroimaging of primary headache disorders. Curr Neurol Neurosci Rep 4: 105-110, 2004.